Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Motixafortide · 1 trial · 3 indications
Complete response is defined as the disappearance of all lesions. Partial response is defined as ≥30% decrease in the sum of diameters of target lesions, in the absence of CR, new lesions, and unequivocal progression in non-target lesions.
| Arm | Type | Description |
|---|---|---|
| Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel | EXPERIMENTAL | Participants will receive standard FDA-approved doses of gemcitabine and nab-paclitaxel for pancreas cancer and cemiplimab at the dose that is approved for participants with skin cancer. Participants will also receive motixafortide at a dose that has been deemed safe in previous studies when used in combination with immunotherapy and chemotherapy. If the combination study treatment causes a serious side effect in participants, the study treatment will be modified. |
| Name | Type | Description |
|---|---|---|
| Motixafortide | DRUG | 1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly |
| Cemiplimab | DRUG | 350 mg intravenous (IV) once every 21 days |
| Gemcitabine | DRUG | 1000 mg/m2 IV on days days 1, 8, 14 (every 28 days) |
| Nab paclitaxel | DRUG | 125 mg/m2 IV on days 1, 8, 14 (every 28 days) |
Inclusion criteria: 1. Histological or pathological confirmation of metastatic pancreas adenocarcinoma 1. Cytologic or histologic proof of pancreas adenocarcinoma needs to be verified by the treating institution pathologist, either from the initial diagnostic biopsy or from the required pre-tre...
Top 20 of 68 competitors
Motixafortide is an investigational small molecule being studied for the treatment of pancreatic cancer, specifically pancreatic adenocarcinoma. It is currently in Phase 2 clinical development as a combination therapy with immunotherapy and chemotherapy. The drug is being evaluated in a clinical trial for patients with this condition.
Motixafortide is a peptide-based small molecule that targets chemokine receptors. It is being studied for its role in modulating the tumor microenvironment to enhance the effects of immunotherapy and chemotherapy in pancreatic cancer. The drug's mechanism involves inhibiting chemokine signaling, which may help improve treatment outcomes.
Motixafortide is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol REGN. Regeneron is conducting clinical trials to evaluate the drug's safety and efficacy in patients with pancreatic cancer.
Motixafortide is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is recruiting patients to assess the combination of Motixafortide with immunotherapy and chemotherapy in pancreatic adenocarcinoma.
Motixafortide is being evaluated in a Phase 2 clinical trial with the identifier NCT04543071, titled "Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma." This trial is recruiting patients in the United States and aims to enroll 10 participants with pancreatic cancer.
Motixafortide is also known by the alternative name BL-8040. It is a peptide-based small molecule being developed by Regeneron Pharmaceuticals for the treatment of pancreatic cancer. The drug is currently in Phase 2 clinical trials, and no alternative names beyond BL-8040 have been disclosed.